Six-Year Immunologic Recovery and Virological Suppression of HIV Patients on LPV/r-Based Second-Line Antiretroviral Treatment: A Multi-Center Real-World Cohort Study in China
The World Health Organization guidelines recommend lopinavir/ritonavir (LPV/r) as a second-line antiretroviral therapy (ART) for HIV-infected adults in middle-income and low-income countries as a protease inhibitor boost based on clinical trials; however, the real-world safety and efficacy remain un...
Saved in:
Main Authors: | Xiaojie Huang (Author), Liumei Xu (Author), Lijun Sun (Author), Guiju Gao (Author), Weiping Cai (Author), Yanfen Liu (Author), Haibo Ding (Author), Hongxia Wei (Author), Ping Ma (Author), Min Wang (Author), Shuiqing Liu (Author), Yaokai Chen (Author), Xiaohong Chen (Author), Qingxia Zhao (Author), Jianhua Yu (Author), Yuxia Song (Author), Hui Chen (Author), Hao Wu (Author), Shanfang Qin (Author), Linghua Li (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2019-12-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Anthropometric and immunological success of antiretroviral therapy and prediction of virological success in west African adults
by: Eugène Messou, et al.
Published: (2008) -
Virologic and immunologic status of children with HIV-TB co-infections
by: Djatnika Setiabudi, et al.
Published: (2021) -
Immunological status and virological suppression among HIV-infected adults on highly active antiretroviral therapy
by: Mulugeta Melku, et al.
Published: (2020) -
Virological and immunological characteristics of HIV-infected individuals at the earliest stage of infection
by: Jintanat Ananworanich, et al.
Published: (2016) -
Switch to fixed-dose ainuovirine, lamivudine, and tenofovir DF versus elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in virologically suppressed people living with HIV-1: the 48-week results of the SPRINT trial, a multi-centre, randomised, double-blind, active-controlled, phase 3, non-inferiority trialResearch in context
by: Fujie Zhang, et al.
Published: (2024)